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Abstract   
 
 
Background:  Morbidly obese individuals carry with them the burden of possibly developing related 
conditions including hypertension, Type 2 Diabetes, stroke, sleep apnea, and myocardial infarction.  
Obesity has become a serious and life changing condition that has long term complications and 
consequences if left untreated.  Roux-en-Y gastric bypass surgery has become the most widely used 
method in the treatment of morbid obesity and control of Type 2 Diabetes. 
 
Hypothesis:  Roux-en-Y gastric bypass surgery provides a more effective approach to morbid obesity 
and Type 2 Diabetes. 
 
Study Design:  Exhaustive search of available medical literature 
 
 
Methods:  Literature search of  CINAHL, PubMed, Ovid, Google Scholar, EJournals and search terms 
Roux-en-y, bariatric surgery, diabetes, surgery for obesity 
 
Results:  The studies reviewed confirmed that Roux-en-Y gastric bypass provides significant 
improvement in weight loss and modification of Type 2 Diabetes.   
 
Conclusion:  When factors such as Type 2 Diabetes secondary to or contributing to morbid obesity, 
Roux-en-Y gastric bypass surgery should be a strong consideration  
 
Keywords:  NIDDM, insulin resistance, Roux-en-Y gastric bypass, morbid obesity 
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The Effectiveness of Roux-en-Y Bariatric Surgery Technique on Weight Loss and 
Diabetic Medication Reduction in Type 2 Morbidly Obese Adults Compared to 
Other Methods 
 
Introduction 
     According to MedicineNet.com, obesity is defined as “the state of being well above one’s  
 
normal weight”.1  The site concedes that “traditionally” an individual’s obesity has been based 
 
 on a greater than 20 percent increase above their ideal weight with height, age, sex, and build  
 
considered.  Moreover, BMI (body mass index), is also an important factor to consider with  
 
obesity.  This index relates a person’s body weight to their height, calculated by dividing a  
 
person’s weight in kilograms by their height in meters squared.  This equation establishes total  
 
body fat content in adults.  The National Institutes of Health more specifically define obesity as  
 
having a BMI of 30 and above.1 
 
     The turn of the century has seen a significant rise in the weight of American adults.  Obesity in  
 
America has become not only a serious medical condition but one of the most widespread  
 
chronic medical conditions.  Data from the National Health and Nutrition Examination Survey 
  
(2001-2004) report that one third of adults in the United States are obese.  A cause for alarm 
  
stems from the fact that obesity is directly related to Non-Insulin Dependent Diabetes (NIDDM), 
 
 also known as Type 2 Diabetes.  NIDDM causes nephropathy, retinopathy, neuropathy, and  
 
atherosclerosis.  Approximately 80% of patients with NIDDM are obese.8 
 
NIDDM is characterized by initial insulin resistance.  Insulin is a hormone produced by the liver.   
 
It is required for the transport of blood glucose into muscle cells and fat cells to be used for  
 
energy.  The act of transporting glucose into the cells allows insulin to keep blood glucose  
 
levels within a normal range.  Insulin resistance occurs when glucose is no longer transported  
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into cells by insulin.  Fat cells tend to be more insulin resistant than muscle cells, hence, the  
 
significant role obesity plays in insulin resistance and Type 2 Diabetes.3,4,5  Initially, when the  
 
pancreas detects insulin  resistance, it produces more insulin.  Blood glucose levels can remain  
 
normal, as long as there is  enough insulin to compensate for the resistance.  Type 2 Diabetes  
 
arises when the pancreas can  no longer produce high levels of insulin which results in a rise in 
  
blood glucose levels.  As the degree and duration of obesity increases, so does the risk of Type 2  
 
Diabetes.   
 
The safest and most effective way to treat morbidly obese individuals with Type 2  
 
Diabetes has been debated for years among physicians, scientists, and researchers.  The studies  
 
propose, as bariatric surgery evolves, surgeons and physicians have begun to see less surgical  
 
complication and positive results in weight loss and amelioration in comorbid conditions including  
 
Type 2 Diabetes.  Dr. Walter J. Pories of the East Carolina University School of Medicine discovered  
 
the ineffectiveness of diets in over half (55.9%) of the morbidly obese group of patients with indicators  
 
of abnormal glucose metabolism.  He reported the general course of the individuals was a pattern of  
 
continuous, increased weight, worsening diabetes, and ongoing development of diabetic  
 
complications.9   
 
     Studies published in Diabetic Care concede that, “eleven to 36 percent of patients with NIDDM 
 
 no longer respond well to diet and sulfonylurea therapy after one year of treatment.  Usually,  
 
they are then treated with insulin, which induces hyperinsulinemia and possibly the  
 
development of atherosclerosis. These possibilities have led to the view that neither insulin 
 
 alone nor combined treatment with insulin and sulfonylurea is satisfactory”.10,11  Years later, Dr.  
 
Pories reported that, NIDDM patients rarely return to long-term normal blood glucose  
 
concentration using a common therapy of insulin, diet, exercise, behavior modification, and  
 
oral medication.  Also, the complications of diabetes, including stroke, myocardial infarction,  
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loss of vision, renal failure, limb amputation, and neuropathies, are not reduced. 
 
     In 1967, the first open Roux-en-Y gastric bypass surgery (RYGB) was performed by Dr. Mason  
 
and Dr. Ito as treatment for obesity.  Initially, the idea of gastric bypass originated from weight  
 
loss observed in patients undergoing partial stomach removal for ulcers.2  Dr. Alan Wittgrove 
 
 and Dr. Wesley Clark of the Center for Surgical Weight Control first developed the laparoscopic  
 
gastric bypass technique in 1993.  The surgeons developed this technique to minimize incision  
 
infections and late incisional hernia that arise postoperatively, in a small percentage of patients  
 
who undergo open Roux-en-Y surgery.  To avoid bile reflux, the operation was modified using a  
 
“Roux-en-Y” limb of the intestine, connected to a 20mm pouch of the stomach.  As a result, the  
 
remaining stomach portion and first segment of small intestine are bypassed.2,7  In 2001, the  
 
mini-gastric bypass was introduced as a simpler procedure that allowed for shorter hospital 
  
stay post-surgery.3  Likewise, it is an effective weight loss treatment for morbidly obese patients  
 
and an intervention against related metabolic complications.  For this reason, as well as due to  
 
minimal post-surgical side effects, Roux-en-Y gastric bypass has been found to be the gold  
 
standard procedure over the gastric banding technique and nonsurgical weight loss methods in  
 
several studies including those incorporated in this review.  
 
Methods 
     Published randomized and prospective trials on morbidly obese adults with  
 
comorbities (hypertension, hyperlipidemia, cardiovascular disease, sleep apnea, NIDDM) and the  
 
effects on these comorbities, specifically NIDDM were included. Studies evaluating safety and 
 
efficacy comparisons of  Roux-en-Y bypass surgery with other bariatric surgeries were are included. 
 
Most studies were published in North America; however, studies from Sweden and Taiwan (translated  
 
into English), were also included. Although laboratory values were stated in some of the articles, the  
 
values were excluded, however, relevant information from these articles pertaining to specific  
 
surgeries and comorbities were included. Articles on pediatric or adolescent diabetes and/or surgeries  
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were excluded. Articles that did not include diabetes as a comorbidity were excluded.  There were  
 
articles on superobesity and RYGB that were considered.  These articles did not have significant  
 
information on the superobese and NIDDM.  Therefore, these articles were excluded. 
 
Results 
 
     Kenneth G. MacDonald, Jr, MD et al at East Carolina University School of Medicine, compared a  
 
RYGB/NIDDM/morbidly obese group with a non-RYGB/NIDDM/morbidly obese group (control)  
 
between 1979 and 1994.  The size of the control group (78 patients) treated with oral hypoglycemics or  
 
insulin for their NIDDM, increased from 56.4% to 87.5% from initial contact to last contact.  The  
 
individuals in the surgical group (127 patients) needing medical management of their diabetes  
 
decreased from 31.8% post-surgical to 8.6% from at the last time of contact.4    
 
     Harvey J. Sugerman, MD et al at the Medical College of Virginia conducted a trial in which  
 
morbidly obese patients underwent conversion to GBP after complications of VBG (43 patients) or  
 
failure to lose weight after VBG surgery (15 patients).  At one year follow-up after the conversion  
 
surgery, the percentage of excess weight loss among the 53 patients was 36% +/- 24% to 76%+/-18%.   
 
In patients who could be contacted over a period of eight years, weight loss was continual.5 
 
     Wei-Jei Lee, MD, PhD et al at En-Chu Kong Hospital in Taiwan, conducted a trial comparing  
 
Roux-en-Y gastric bypass (LRYGBP) technique to a laparoscopic mini-gastric bypass (LMGBP) for  
 
the treatment of morbid obesity.  The percentage of excess weight loss at one year was 58.7% in the  
 
LRYGBP group and 64.9% in the LMGBP group.  The percentage of excess weight loss at two years  
 
was 60.0% in the LRYGBP group and 64.4% in the LMGBP group.  The authors indicate that LMGBP  
 
is simpler than LRYGBP.  However, they are both acceptable and effective treatments for weight loss  
 
in morbidly obese patients with metabolic syndrome (including NIDDM).3 
 
     John A. Batsis, MBBCh et al at Mayo Clinic in Rochester, MN conducted a study of patients with a 
body mass index of 35 or greater and metabolic syndrome components.  They compared these patients, 
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180 had Roux-en-Y gastric bypass surgery and 157 did not have surgery.  Instead, the nonsurgical 
group was evaluated in a weight-reduction program.  Increased fasting plasma glucose was one of the 
components.  The study considered patients to have diabetes mellitus if they were taking oral 
hypoglycemic medication or insulin or if they had fasting glucose level of 126 mg/dL (without a 
diagnosis of DM).  In the surgical group, 156 out of 180 patients with MetS decreased to 36 patients 
and all components (including DM) of metabolic syndrome were improved with a decrease in use of 
medication.  Of the nonsurgical group, 133 out of 157 patients with MetS decreased to 117 patients. 
That is an 87% decrease to 29% of patients in the surgical group and only 85% to 75% decrease in the 
nonsurgical group.  The study concluded that 2.1 individuals needed to be treated to achieve resolution 
in one case of metabolic syndrome.6   
Discussion 
     Indeed, the bottom line for all four studies reviewed is that the Roux-en-Y gastric bypass technique  
 
produces effective results in weight loss and a reduction in the use of  hyperglycemic agents in  
 
morbidly obese patients with Type 2 Diabetes.  The two studies that focused on comparing weight loss  
 
and diabetic medication management in a control and surgical group, contend that the techniques of the  
 
Roux-en-Y gastric bypass is a significant factor in weight loss.5,6  Moreover, the studies question  
 
whether baseline diabetes status play a role in the weight loss, as well as rapid reduction in comorbid  
 
conditions, including diabetes.5,6  Although the MacDonald study was unable to gather sufficient  
 
follow-up data concerning weight in the control group, investigators were able to determine medical  
 
management of diabetes.4  Likewise, the Mayo Clinic did not consider their study to have a “true”  
 
control group compatible with a generalized patient base attempting to lose weight using nonsurgical  
 
methods.  The investigators suggest that the findings for their control group can only be applied to  
 
obese individuals with a BMI of 35– 39.9 (class II) and a BMI ≥ 40 (class III), who have been  
 
evaluated for RYGB gastric bypass surgery.6  The challenge of forming a control group for both  
 
studies poses limitations regarding other bariatric surgeries and individuals more compatible with the  
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surgical subjects. 
 
     The remaining studies in this review compared the Roux-en-Y gastric bypass technique to other  
 
surgical techniques for the treatment of morbid obesity .3,5  the Taiwan study concedes that the Roux- 
 
en-Y technique is the “gold standard” based on its effect on weight loss in other randomized trials.   
 
However, the study attributes the mini-gastric bypass as having similar results in weight reduction, as  
 
well as a less intricate and safer operation.3  The Sugerman study noted a significant resolution of  
 
surgical side effects when patients were converted from the vertical banded gastroplasty to Roux-en-Y  
 
gastric bypass.  The study also acknowledges the safety factor of the conversion surgery.  Although  
 
investigators achieved complete weight loss follow-up results at one and two years, they were only  
 
able to accomplish a 45% follow-up at five years.    
     
 Conclusion 
     
     The relationship between obesity and diabetes involves high food intake.  This  
 
relationship has been incredibly frustrating and disappointing for both physician and patient alike, in  
 
the treatment of weight loss as well as diabetes.  Understandably, most patients are apprehensive about 
 
surgery as an option for weight loss.  Moreover, there are morbidly obese patients who are not 
 
psychologically prepared for such a life altering change in their appearance and in the emotional 
 
escape that increased food intake provides them.  This creates a certain amount of discouragement 
 
among patients and physician, leading to exhaustive weight loss  treatments of diet and exercise for 
 
patients.  Although glucose metabolism can be improved with diet modification in an obese individual, 
 
it is usually short term and fractional.  As indicated in the Mayo Clinic study, the nonsurgical group  
 
had more individuals with unresolved Type 2 Diabetes  and increased number were on insulin.6 
 
     Inevitably, when the decision is made to undergo surgery, euphamistically referred to as the option  
 
of  last resort, the choice most often is Roux-en-y gastric bypass over gastric banding.  Although  
 
RYGB is not a cure for NIDDM, it offers a rapid, but safe return to normal glucose range before  
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substantial weight loss is achieved.  Normal levels are observed and maintained as early as the third or  
 
fourth days post-surgery without insulin.  Researchers at the Medical College of Virginia acknowledge  
 
that other surgical methods, like gastric banding, are successful treatments for weight loss only, but  
 
does not contribute directly to reducing diabetic medication use and comorbidities or contributing  
 
factors of morbid obesity although there is an indirect effect based on achieving weight loss.5  The  
 
technique only allows for gradual adjustment of stomach size over time.  By making the stomach  
 
smaller over time, an individual feels full, thus decreasing their desire to continue to eat.  The Roux- 
 
en-Y gastric bypass technique of disconnecting the duodenum (top of the small intestine) and attaching  
 
the remainder of the small intestine to a small pouch of the stomach, has been found to be a very  
 
effective way of directly causing a remittance of Type 2 Diabetes in morbidly obese patients.   
 
Researchers believe when food skips the first part of the intestinal tract, there is a change in hormonal  
 
regulation of blood sugar.  This theory, as well as studies similar to the one in this review, influenced  
 
Dr. Francesco Rubino, Director of the Diabetes Surgery Center at New York-Presbyterian  
 
Hospital/Weill Cornell Medical Center.  His study used rats with Type 2 Diabetes.  He found that once  
 
the duodenum is reattached and food is no longer being blocked from it, the rats resume Type 2  
 
diabetes characteristics.12  
 
     Treatment for morbid obesity and Type 2 Diabetes has definitely come a long way and there is still  
 
more to discover as obesity continues to be a long term health dilemma in the United States and around  
 
the world.  It is comforting to know, despite the risks involved, there are now successful options for  
 
treating obesity related Type 2 Diabetes.  Perhaps similar studies involving adolescents, superobese,  
 
and specific racial groups with NIDDM would be helpful.  Also, studies that focus on the relationship  
 
between specific antidiabetic medications and gastric bypass surgery would provide information to  
 
researchers, physicians, and pharmaceutical companies.  Nevertheless, patients with Type 2 Diabetes  
 
should  be aware of the risk and benefits of any weight loss option considered.  
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Figure 1. 
Roux-en-Y gastric bypass and mini-bypass illustrations13 
 
 
 
 
 
Figure 2. 
Verticle Banded Gastroplasty illustration14 
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